(Q42989123)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

13

Hiromitsu Kumada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

4

Fumitaka Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

2

Kenji Ikeda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

7

Masahiro Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

5

Yoshiyuki Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

8

Norio Akuta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1

Yasuji Arase

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

11

Hitomi Sezaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

6

Satoshi Saitoh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

12

Mariko Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

9

Takashi Someya

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Akihito Tsubota

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

355-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection

5 January 2020

cites work

1 reference

The treatment of chronic viral hepatitis

21 January 2018

1 reference

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

21 January 2018

1 reference

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

21 January 2018

1 reference

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

21 January 2018

1 reference

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.

21 January 2018

1 reference

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks

21 January 2018

1 reference

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

21 January 2018

1 reference

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease

21 January 2018

1 reference

Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C.

21 January 2018

1 reference

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

21 January 2018

1 reference

Detection of hepatitis C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity

21 January 2018

1 reference

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000080880

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15564748%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference